Baseline Characteristics for 124 Patients
| Characteristic | All patients (n = 124) |
| Age (y) | 73 (66–77) |
| Time since diagnosis of prostate cancer (y) | 7 (4–11) |
| Gleason score at diagnosis* | |
| <8 | 41 (36%) |
| ≥8 | 74 (64%) |
| M status at diagnosis | |
| M0 | 79 (64%) |
| M1 | 45 (36%) |
| Primary treatments | |
| Prostatectomy ± lymphadenectomy | 72 (58%) |
| Local radiotherapy | 15 (12%) |
| Systemic treatment | 37 (30%) |
| PSA (ng/mL) | 137 (35–347) |
| Lactate dehydrogenase (U/L) | 264 (217–349) |
| Total alkaline phosphatase (U/L) | 121 (72–247) |
| Hemoglobin (g/dL) | 11.2 (9.9–12.3) |
| ECOG performance status | |
| 0 | 28 (23%) |
| 1 | 87 (70%) |
| 2 | 9 (7%) |
| Pain status at baseline† | |
| Symptomatic disease | 77 (62%) |
| Asymptomatic disease | 47 (38%) |
| Previous systemic treatments | |
| Androgen deprivation therapy | 124 (100%) |
| Docetaxel | 94 (76%) |
| Cabazitaxel | 20 (16%) |
| Previous chemotherapy | 96 (77%) |
| Abiraterone or enzalutamide or both | 124 (100%) |
| 223Ra | 24 (19%) |
| Prior lines of systemic treatments | |
| 1 | 8 (6%) |
| ≥2 | 116 (94%) |
| ≥3 | 70 (56%) |
| ≥4 | 27 (22%) |
| ≥5 | 6 (5%) |
| Sites of disease on PSMA PET | |
| Bone | 116 (94%) |
| Lymph nodes | 101 (81%) |
| Viscera‡ | 38 (31%) |
| Bone + lymph nodes | 92 (74%) |
| Bone + lymph nodes + viscera | 28 (23%) |
* Data were missing for 9 patients.
† Symptomatic disease was defined as presence of pain or use of opioids for cancer-related pain at treatment initiation; asymptomatic disease was defined as no pain and no opioid use at baseline.
‡ Viscera include lungs, liver, and adrenal glands.
ECOG = Eastern Cooperative Oncology Group.